Other Events ·
GSK plc received Orphan Drug Designations (ODD) from the US Food and Drug Administration and the European Medicines…
GSKGSK plc
GSK plc received Orphan Drug Designations (ODD) from the US Food and Drug Administration and the European Medicines Agency for momelotinib to treat VEXAS syndrome. VEXAS is a rare, life-threatening haematological condition with no currently approved treatments and a 30-40% five-year mortality rate. The company is currently conducting the phase II/III ATLAS trial to evaluate the efficacy and safety of momelotinib for this indication. Momelotinib is a JAK inhibitor already approved in several regions for the treatment of myelofibrosis. GSK is a global biopharmaceutical company that develops medicines to treat various diseases.